What is a serous borderline ovarian tumour?
A serous borderline ovarian tumour (SBOT) is an ovarian growth that sits between a harmless cyst and an ovarian cancer. Its cells look more active than those of a benign cyst, but they do not invade the surrounding tissue in the way a true cancer does. Doctors also call these tumours “tumours of low malignant potential” or atypical proliferative serous tumours.
“Serous” describes the type of cell. These cells resemble the lining of the fallopian tube and produce a watery fluid. Serous tumours are the most common kind of borderline ovarian tumour.
Unlike most ovarian cancers, SBOTs often affect younger women, many of whom have not yet completed their families. About a third of women are under 40 at diagnosis. This is why fertility-sparing surgery is a central part of treatment planning (Carbonnel et al., 2021).
The outlook is very good. Most women are cured by surgery alone, and deaths are rare. However, the tumour can come back, especially in the remaining ovary, and a small number of cases later turn into a low-grade serous cancer. Long-term follow-up is therefore recommended (Prat and De Nictolis, 2002).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Borderline (low malignant potential) epithelial tumour of the ovary |
| Also called | Atypical proliferative serous tumour; tumour of low malignant potential |
| How common | Borderline tumours are 10-20% of epithelial ovarian tumours; about half are serous |
| Typical age | Usually 30-50; a third under 40 |
| Both ovaries | Involved in roughly a third of cases |
| Stage at diagnosis | About two-thirds confined to the ovary or ovaries |
| Main treatment | Surgery, often preserving fertility |
| Chemotherapy | Rarely needed |
| Outlook | Excellent; survival over 95% at 10 years in most series |
2. Types of serous borderline tumour
| Type | Features | Behaviour |
|---|---|---|
| Typical (usual) SBOT | Branching papillae lined by layered cells | Very favourable |
| Micropapillary variant | Long, thin papillae arising directly from thick stalks | More often bilateral and associated with implants; still mostly favourable |
| SBOT with microinvasion | Tiny foci of invasion under about 5 mm | Behaves much like typical SBOT |
Implants outside the ovary
In about a third of women, small deposits called implants are found on the lining of the pelvis or abdomen.
| Implant type | Meaning |
|---|---|
| Non-invasive implants | Deposits on the surface; usually behave in a benign way |
| Invasive implants | Deposits that destroy underlying tissue; now classed as low-grade serous carcinoma |
The distinction matters: in a long-term study, poor outcomes were seen almost only in women whose implants were invasive (Prat and De Nictolis, 2002).
How it compares with other ovarian growths
| Growth | Invades tissue? | Usual treatment | Outlook |
|---|---|---|---|
| Benign serous cystadenoma | No | Removal of the cyst or ovary | Cured |
| Serous borderline tumour | No (or only tiny foci) | Surgery, often fertility-sparing | Excellent |
| Low-grade serous carcinoma | Yes | Surgery, then hormone therapy or chemotherapy | Slow-growing but can recur |
| High-grade serous carcinoma | Yes | Surgery and chemotherapy | Serious |
3. Causes and risk factors
The cause of SBOT is not fully understood. Many experts think these tumours start from cells of the fallopian tube or from small inclusion cysts in the ovary.
| Factor | Notes |
|---|---|
| Age | Mainly women of reproductive age and in their 40s |
| Infertility | Some studies show a modest link |
| Not having children | Associated with ovarian tumours in general |
| Use of the contraceptive pill | May lower the risk |
Gene changes
| Gene change | Notes |
|---|---|
| KRAS mutation | Common |
| BRAF mutation | Common; may be linked with a lower risk of progression to cancer |
| ERBB2 and other changes | Seen in a minority |
These changes occur only in the tumour and are not inherited. SBOT is not usually linked with BRCA gene mutations.
4. How does it look
On the ovary
| Feature | Description |
|---|---|
| Shape | A cyst with fine, frond-like growths inside or on the surface |
| Size | Often 5-10 cm, but can be larger |
| Contents | Clear, watery fluid |
| Surface growths | Present in some; linked with a higher chance of implants |
| Both sides | One or both ovaries may be affected |
On scans
Transvaginal ultrasound usually shows a cyst with papillary projections, which are small solid bumps on the inner wall. Blood flow may be seen within these projections. MRI helps to tell a borderline tumour from a benign cyst or invasive cancer and can show whether the other ovary is involved. CT is used when spread in the abdomen is suspected.
Under the microscope
| Feature | Description |
|---|---|
| Papillae | Branching, tree-like folds lined by serous cells |
| Cell layering | Cells pile up in several layers and bud off into the cyst |
| Atypia | Mild to moderate |
| Invasion | Absent, or limited to tiny microinvasive foci |
| Psammoma bodies | Small calcified spheres are common |
5. Symptoms
Many SBOTs cause no symptoms and are found by chance on an ultrasound done for another reason.
Common symptoms
- Pain or discomfort in the lower abdomen or pelvis
- Bloating or a feeling of fullness
- A swelling of the abdomen
- Changes in periods
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Sudden severe pain | Twisting (torsion) or rupture of the cyst |
| Passing urine more often | Pressure on the bladder |
| Constipation | Pressure on the bowel |
| Fluid in the abdomen | Can occur with implants |
| Difficulty getting pregnant | Found during fertility investigations |
When to seek medical advice
See a doctor if you have bloating, pelvic pain, feeling full quickly or needing to pass urine more often on most days for more than a few weeks. Seek urgent care for sudden severe pelvic pain.
6. Diagnosis
| Test | Purpose |
|---|---|
| Pelvic examination | Checks for a mass |
| Transvaginal ultrasound | Main test for describing the cyst |
| MRI | Clarifies uncertain ultrasound findings |
| CA-125 blood test | Often mildly raised; not specific |
| CT scan | Looks for spread in the abdomen |
| Surgery and pathology | The only way to confirm the diagnosis |
A frozen section (quick examination of tissue during surgery) can suggest the diagnosis, but it sometimes under-calls or over-calls the tumour, so the final answer comes from the full laboratory report (Gershenson, 2017).
Staging
SBOTs are staged with the FIGO system for ovarian tumours.
| Stage | What it means |
|---|---|
| Stage I | Confined to one or both ovaries |
| Stage II | Spread within the pelvis |
| Stage III | Implants in the abdomen or lymph node involvement |
| Stage IV | Distant spread; very rare |
7. Treatment
Treatment is planned by a gynaecological oncology team, ideally with a fertility specialist when relevant.
Surgery
| Option | Who it suits | Notes |
|---|---|---|
| Ovarian cystectomy | Young women, especially with tumours in both ovaries | Keeps the most ovarian tissue; higher recurrence risk |
| Unilateral salpingo-oophorectomy | Young women with one ovary affected | Removes the affected ovary and tube |
| Total hysterectomy and both ovaries | Women who have completed their families or are past the menopause | Lowest recurrence risk |
| Staging procedures | Most women | Fluid washings, omentectomy and biopsies of the abdominal lining |
Routine removal of lymph nodes is not recommended, because it does not improve survival (Gershenson, 2017). Surgery can often be done by keyhole (laparoscopic) methods.
Fertility-sparing surgery
Keeping the uterus and at least part of one ovary allows many women to conceive naturally. The trade-off is a higher chance of recurrence, usually as another borderline tumour in the remaining ovary, which can generally be treated with further surgery. In a French series of 65 women with more advanced SBOT treated conservatively, 58% had a recurrence, but 20 women went on to have 24 pregnancies (Gouy et al., 2021).
Chemotherapy and other treatment
| Situation | Approach |
|---|---|
| Stage I, completely removed | No further treatment |
| Non-invasive implants | Usually no further treatment |
| Invasive implants or low-grade serous carcinoma | Treated as low-grade serous cancer, possibly with hormone therapy or chemotherapy |
Pregnancy and fertility after treatment
| Topic | What to know |
|---|---|
| Trying to conceive | Many women try soon after recovery, once follow-up scans are clear |
| Fertility treatment | Ovarian stimulation and IVF have been used; plans are made with the cancer team |
| Egg or embryo freezing | Can be discussed before surgery if both ovaries are affected |
| During pregnancy | Ultrasound follow-up usually continues |
| After the family is complete | Some women choose to have the remaining ovary removed |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Keyhole surgery | Often a day case or 1-2 nights in hospital |
| Open surgery | Around 3-5 nights in hospital |
| Recovery | Light activity within 1-2 weeks; full recovery in 4-6 weeks |
| Results | The full pathology report usually takes 1-3 weeks |
Side effects
| Treatment | Possible side effects |
|---|---|
| Keyhole surgery | Shoulder-tip pain, bloating, small wound problems |
| Removal of one ovary | Usually no change in hormones; fertility often maintained |
| Removal of both ovaries | Immediate menopause if not already menopausal |
| Omentectomy | Generally few long-term effects |
8. Outlook (prognosis)
| Situation | Usual outcome |
|---|---|
| Stage I | Close to 100% survival |
| Advanced stage with non-invasive implants | Very good survival, though recurrence is more common |
| Invasive implants | Outlook similar to low-grade serous carcinoma |
| After fertility-sparing surgery | More recurrences, but survival is not reduced in most studies |
Recurrence may appear many years after the first operation. Most recurrences are borderline tumours again, but a small proportion are low-grade serous carcinoma (Prat and De Nictolis, 2002).
Why recurrence is more common after fertility-sparing surgery
When an ovary or part of an ovary is kept, the remaining ovarian tissue can develop a new borderline tumour. This is especially likely after a cystectomy, where only the cyst is removed. Most of these recurrences are found on routine ultrasound before they cause symptoms, and they are usually treated with another operation. Women weigh this extra risk against the chance of natural pregnancy and of avoiding an early menopause, ideally after a detailed discussion with their surgeon.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review every 6 months for the first few years | Checks symptoms and examination |
| Transvaginal ultrasound | Especially important if an ovary was kept |
| CA-125 | Helpful if it was raised at diagnosis |
| Yearly review afterwards | Continued for at least 10 years in many centres |
| Completion surgery | Sometimes discussed after childbearing is complete |
10. Living with a serous borderline ovarian tumour
- Attend follow-up scans, particularly if you still have ovarian tissue
- Talk to a fertility specialist if you plan to have children
- Ask about menopause symptom relief if both ovaries were removed
- Report new pelvic pain or bloating without waiting for your next appointment
- Seek support from ovarian cancer charities, which also help women with borderline tumours
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is a borderline tumour cancer? | Not quite; it is a low-risk tumour that does not usually invade |
| Will I need chemotherapy? | Very rarely |
| Can I still have children? | Often yes, with fertility-sparing surgery |
| Can it come back? | Yes, mainly in a remaining ovary; it can usually be removed again |
| Can it turn into cancer? | Occasionally, usually a slow-growing low-grade serous cancer |
| Is it inherited? | Not usually |
| Is IVF safe afterwards? | Many women have had successful treatment; discuss timing with your team |
| Do I need my lymph nodes removed? | No, routine lymph node removal is not recommended |
| Will my periods stop? | Not if at least part of one ovary is kept |
12. Questions to ask your care team
- Is my tumour the typical or micropapillary type?
- Were there any implants, and were they invasive or non-invasive?
- Can my fertility be preserved?
- What is my risk of recurrence?
- How often will I need scans, and for how long?
- Should I consider further surgery once my family is complete?
Resources
- Carbonnel, M. et al. (2021) ‘Serous borderline ovarian tumor diagnosis, management and fertility preservation in young women’, Journal of Clinical Medicine, 10(18), 4233.
- Gershenson, D.M. (2017) ‘Management of borderline ovarian tumours’, Best Practice and Research Clinical Obstetrics and Gynaecology, 41, pp. 49-59.
- Gouy, S. et al. (2021) ‘Results after conservative surgery of stage II/III serous borderline ovarian tumors’, Annals of Surgical Oncology, 28(7), pp. 3597-3604.
- Prat, J. and De Nictolis, M. (2002) ‘Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion’, American Journal of Surgical Pathology, 26(9), pp. 1111-1128.
- National Cancer Institute (2026) Ovarian Low Malignant Potential Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-low-malignant-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.